Dr. Araz Marachelian, MD
Claim this profileChildren's Hospital Los Angeles
Studies Neuroblastoma
Studies Cancer
8 reported clinical trials
20 drugs studied
Area of expertise
1Neuroblastoma
Stage IV
ALK positive
MYC positive
2Cancer
Stage IV
Affiliated Hospitals
Clinical Trials Araz Marachelian, MD is currently running
Dinutuximab + Chemotherapy
for High-Risk Neuroblastoma
This phase III trial tests how well the addition of dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy works for treating children with newly diagnosed high-risk neuroblastoma. Dinutuximab is a monoclonal antibody that binds to a molecule called GD2, which is found on the surface of neuroblastoma cells, but is not present on many healthy or normal cells in the body. When dinutuximab binds to the neuroblastoma cells, it helps signal the immune system to kill the tumor cells. This helps the cells of the immune system kill the cancer cells, this is a type of immunotherapy. When chemotherapy and immunotherapy are given together, during the same treatment cycle, it is called chemoimmunotherapy. This clinical trial randomly assigns patients to receive either standard chemotherapy and surgery or chemoimmunotherapy (chemotherapy plus dinutuximab) and surgery during Induction therapy. Chemotherapy drugs administered during Induction include, cyclophosphamide, topotecan, cisplatin, etoposide, vincristine, and doxorubicin. These drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing or by stopping them from spreading. Upon completion of 5 cycles of Induction therapy, a disease evaluation is completed to determine how well the treatment worked. If the tumor responds to therapy, patients receive a tandem transplantation with stem cell rescue. If the tumor has little improvement or worsens, patients receive chemoimmunotherapy on Extended Induction. During Extended Induction, dinutuximab is given with irinotecan, temozolomide. Patients with a good response to therapy move on to Consolidation therapy, when very high doses of chemotherapy are given at two separate points to kill any remaining cancer cells. Following, transplant, radiation therapy is given to the site where the cancer originated (primary site) and to any other areas that are still active at the end of Induction. The final stage of therapy is Post-Consolidation. During Post-Consolidation, dinutuximab is given with isotretinoin, with the goal of maintaining the response achieved with the previous therapy. Adding dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy may be better at treating children with newly diagnosed high-risk neuroblastoma.
Recruiting2 awards Phase 37 criteria
Biology Study
for Neuroblastoma
Medical scientists want to find better ways to treat neuroblastoma and to find ways to prevent the tumor from growing back. To do this, they need more information about the characteristics of neuroblastoma cells. Therefore, they want to study samples of neuroblastoma tissues and neuroblastoma and normal cells in the blood and bone marrow that may be related to the growth of neuroblastoma cells. Doctors and other medical scientists also want to find better ways to detect and measure neuroblastoma to improve the ability to follow the response of tumor cells to therapy.
Recruiting1 award N/A4 criteria
More about Araz Marachelian, MD
Clinical Trial Related4 years of experience running clinical trials · Led 8 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Araz Marachelian, MD has experience with
- Dinutuximab
- Lorlatinib
- Vorinostat
- 131I-MIBG
- Tissue Sample Collection
- Blood Sample Collection
Breakdown of trials Araz Marachelian, MD has run
Neuroblastoma
Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Araz Marachelian, MD specialize in?
Araz Marachelian, MD focuses on Neuroblastoma and Cancer. In particular, much of their work with Neuroblastoma has involved Stage IV patients, or patients who are ALK positive.
Is Araz Marachelian, MD currently recruiting for clinical trials?
Yes, Araz Marachelian, MD is currently recruiting for 2 clinical trials in Los Angeles California. If you're interested in participating, you should apply.
Are there any treatments that Araz Marachelian, MD has studied deeply?
Yes, Araz Marachelian, MD has studied treatments such as Dinutuximab, Lorlatinib, Vorinostat.
What is the best way to schedule an appointment with Araz Marachelian, MD?
Apply for one of the trials that Araz Marachelian, MD is conducting.
What is the office address of Araz Marachelian, MD?
The office of Araz Marachelian, MD is located at: Children's Hospital Los Angeles, Los Angeles, California 90027-0700 United States. This is the address for their practice at the Children's Hospital Los Angeles.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.